ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001A37

Pharmacokinetics of apomorphine in parkinsonian patients

Identifieur interne : 001A37 ( PascalFrancis/Corpus ); précédent : 001A36; suivant : 001A38

Pharmacokinetics of apomorphine in parkinsonian patients

Auteurs : E. Nicolle ; P. Pollak ; F. Serre-Debeauvais ; P. Richard ; C. L. Gervason ; E. Broussolle ; M. Gavend

Source :

Fundamental and clinical pharmacology [ 0767-3981 ] ; 1993.

RBID : Pascal:93-0470461

Descripteurs français

Pascal (Inist)
- Apomorphine, Stimulant dopaminergique, Parkinson maladie, Voie souscutanée, Pharmacocinétique, Homme, Voie intraveineuse.

English descriptors

KwdEn :
- Dopamine agonist, Human, Intravenous administration, Parkinson disease, Pharmacokinetics, Subcutaneous administration.

Abstract

Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T_max, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0767-3981`
A02	`01`			`@0 FCPHEZ`
A03		`1`		`@0 Fundam. clin. pharmacol.`
A05				`@2 7`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Pharmacokinetics of apomorphine in parkinsonian patients`
A11	`01`	`1`		`@1 NICOLLE (E.)`
A11	`02`	`1`		`@1 POLLAK (P.)`
A11	`03`	`1`		`@1 SERRE-DEBEAUVAIS (F.)`
A11	`04`	`1`		`@1 RICHARD (P.)`
A11	`05`	`1`		`@1 GERVASON (C. L.)`
A11	`06`	`1`		`@1 BROUSSOLLE (E.)`
A11	`07`	`1`		`@1 GAVEND (M.)`
A14	`01`			`@1 Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie @2 38043 Grenoble @3 FRA @Z 1 aut. @Z 3 aut. @Z 7 aut.`
A14	`02`			`@1 Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques @2 38043 Grenoble @3 FRA @Z 2 aut. @Z 4 aut. @Z 5 aut.`
A14	`03`			`@1 Hôp. Antiquaille, serv. neurologie @2 69321 Lyon @3 FRA @Z 6 aut.`
A20				`@1 245-252`
A21				`@1 1993`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 14711 @5 354000033771820060`
A44				`@0 0000`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 93-0470461`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Fundamental and clinical pharmacology`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T_max, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR`
C03	`02`	`X`	`FRE`	`@0 Stimulant dopaminergique`
C03	`02`	`X`	`ENG`	`@0 Dopamine agonist`
C03	`02`	`X`	`SPA`	`@0 Estimulante dopaminérgico`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @2 NM`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM`
C03	`04`	`X`	`FRE`	`@0 Voie souscutanée`
C03	`04`	`X`	`ENG`	`@0 Subcutaneous administration`
C03	`04`	`X`	`SPA`	`@0 Vía subcutánea`
C03	`05`	`X`	`FRE`	`@0 Pharmacocinétique`
C03	`05`	`X`	`ENG`	`@0 Pharmacokinetics`
C03	`05`	`X`	`SPA`	`@0 Farmacocinética`
C03	`06`	`X`	`FRE`	`@0 Homme`
C03	`06`	`X`	`ENG`	`@0 Human`
C03	`06`	`X`	`SPA`	`@0 Hombre`
C03	`07`	`X`	`FRE`	`@0 Voie intraveineuse`
C03	`07`	`X`	`ENG`	`@0 Intravenous administration`
C03	`07`	`X`	`SPA`	`@0 Vía intravenosa`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @4 INC`
N21				`@1 196`

Format Inist (serveur)

NO :	PASCAL 93-0470461 INIST
ET :	Pharmacokinetics of apomorphine in parkinsonian patients
AU :	NICOLLE (E.); POLLAK (P.); SERRE-DEBEAUVAIS (F.); RICHARD (P.); GERVASON (C. L.); BROUSSOLLE (E.); GAVEND (M.)
AF :	Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie/38043 Grenoble/France (1 aut., 3 aut., 7 aut.); Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques/38043 Grenoble/France (2 aut., 4 aut., 5 aut.); Hôp. Antiquaille, serv. neurologie/69321 Lyon/France (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Fundamental and clinical pharmacology; ISSN 0767-3981; Coden FCPHEZ; France; Da. 1993; Vol. 7; No. 5; Pp. 245-252; Bibl. 19 ref.
LA :	Anglais
EA :	Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T_max, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)
CC :	002B02B06
FD :	Apomorphine; Stimulant dopaminergique; Parkinson maladie; Voie souscutanée; Pharmacocinétique; Homme; Voie intraveineuse
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux pathologie; Système nerveux central pathologie
ED :	Dopamine agonist; Parkinson disease; Subcutaneous administration; Pharmacokinetics; Human; Intravenous administration
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Nervous system diseases
SD :	Estimulante dopaminérgico; Parkinson enfermedad; Vía subcutánea; Farmacocinética; Hombre; Vía intravenosa
LO :	INIST-14711.354000033771820060
ID :	93-0470461

Links to Exploration step

Pascal:93-0470461

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pharmacokinetics of apomorphine in parkinsonian patients</title>
<author><name sortKey="Nicolle, E" sort="Nicolle, E" uniqKey="Nicolle E" first="E." last="Nicolle">E. Nicolle</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Serre Debeauvais, F" sort="Serre Debeauvais, F" uniqKey="Serre Debeauvais F" first="F." last="Serre-Debeauvais">F. Serre-Debeauvais</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, P" sort="Richard, P" uniqKey="Richard P" first="P." last="Richard">P. Richard</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C. L." last="Gervason">C. L. Gervason</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E." last="Broussolle">E. Broussolle</name>
<affiliation><inist:fA14 i1="03"><s1>Hôp. Antiquaille, serv. neurologie</s1>
<s2>69321 Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gavend, M" sort="Gavend, M" uniqKey="Gavend M" first="M." last="Gavend">M. Gavend</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0470461</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0470461 INIST</idno>
<idno type="RBID">Pascal:93-0470461</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A37</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pharmacokinetics of apomorphine in parkinsonian patients</title>
<author><name sortKey="Nicolle, E" sort="Nicolle, E" uniqKey="Nicolle E" first="E." last="Nicolle">E. Nicolle</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Serre Debeauvais, F" sort="Serre Debeauvais, F" uniqKey="Serre Debeauvais F" first="F." last="Serre-Debeauvais">F. Serre-Debeauvais</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, P" sort="Richard, P" uniqKey="Richard P" first="P." last="Richard">P. Richard</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C. L." last="Gervason">C. L. Gervason</name>
<affiliation><inist:fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E." last="Broussolle">E. Broussolle</name>
<affiliation><inist:fA14 i1="03"><s1>Hôp. Antiquaille, serv. neurologie</s1>
<s2>69321 Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gavend, M" sort="Gavend, M" uniqKey="Gavend M" first="M." last="Gavend">M. Gavend</name>
<affiliation><inist:fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Parkinson disease</term>
<term>Pharmacokinetics</term>
<term>Subcutaneous administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Apomorphine</term>
<term>Stimulant dopaminergique</term>
<term>Parkinson maladie</term>
<term>Voie souscutanée</term>
<term>Pharmacocinétique</term>
<term>Homme</term>
<term>Voie intraveineuse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T<sub>max</sub>
, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0767-3981</s0>
</fA01>
<fA02 i1="01"><s0>FCPHEZ</s0>
</fA02>
<fA03 i2="1"><s0>Fundam. clin. pharmacol.</s0>
</fA03>
<fA05><s2>7</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pharmacokinetics of apomorphine in parkinsonian patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NICOLLE (E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>POLLAK (P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SERRE-DEBEAUVAIS (F.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RICHARD (P.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GERVASON (C. L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BROUSSOLLE (E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>GAVEND (M.)</s1>
</fA11>
<fA14 i1="01"><s1>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques</s1>
<s2>38043 Grenoble</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Hôp. Antiquaille, serv. neurologie</s1>
<s2>69321 Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>245-252</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>14711</s2>
<s5>354000033771820060</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0470461</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Fundamental and clinical pharmacology</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T<sub>max</sub>
, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dopamine agonist</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Voie souscutanée</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vía subcutánea</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pharmacocinétique</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Pharmacokinetics</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Farmacocinética</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Voie intraveineuse</s0>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Intravenous administration</s0>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vía intravenosa</s0>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s4>INC</s4>
</fC07>
<fN21><s1>196</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 93-0470461 INIST</NO>
<ET>Pharmacokinetics of apomorphine in parkinsonian patients</ET>
<AU>NICOLLE (E.); POLLAK (P.); SERRE-DEBEAUVAIS (F.); RICHARD (P.); GERVASON (C. L.); BROUSSOLLE (E.); GAVEND (M.)</AU>
<AF>Cent. hosp. univ. Grenoble, clin. neurologique, lab. pharmacologie/38043 Grenoble/France (1 aut., 3 aut., 7 aut.); Cent. hosp. univ., clin. neurologique, dép. neurosci. clin. biologiques/38043 Grenoble/France (2 aut., 4 aut., 5 aut.); Hôp. Antiquaille, serv. neurologie/69321 Lyon/France (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Fundamental and clinical pharmacology; ISSN 0767-3981; Coden FCPHEZ; France; Da. 1993; Vol. 7; No. 5; Pp. 245-252; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at vinous doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the T<sub>max</sub>
, was brief (16±11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7±25.8 min)</EA>
<CC>002B02B06</CC>
<FD>Apomorphine; Stimulant dopaminergique; Parkinson maladie; Voie souscutanée; Pharmacocinétique; Homme; Voie intraveineuse</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux pathologie; Système nerveux central pathologie</FG>
<ED>Dopamine agonist; Parkinson disease; Subcutaneous administration; Pharmacokinetics; Human; Intravenous administration</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Nervous system diseases</EG>
<SD>Estimulante dopaminérgico; Parkinson enfermedad; Vía subcutánea; Farmacocinética; Hombre; Vía intravenosa</SD>
<LO>INIST-14711.354000033771820060</LO>
<ID>93-0470461</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A37 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A37 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:93-0470461
   |texte=   Pharmacokinetics of apomorphine in parkinsonian patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Pharmacokinetics of apomorphine in parkinsonian patients

Pharmacokinetics of apomorphine in parkinsonian patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri